Kineta Announces Participation in the H.C. Wainwright 24th Annual Global Healthcare Conference
Seattle, WA — (September 12, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today th ...
Kineta Announces the Filing of a Registration Statement on Form S-4 with the U.S. SEC Related to the Reverse Merger with Yumanity Therapeutics (YMTX)
BOSTON, Aug. 29, 2022 -- Yumanity Therapeutics, Inc. ("Yumanity") (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying t ...
Kineta Announces Appointment of Thierry Guillaudeux, PhD to Chief Scientific Officer
Kineta Announces Appointment of Thierry Guillaudeux, PhD to Chief Scientific Officer Seattle, WA — (June 28, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company foc ...
Kineta Announces Strategic Research Collaboration and License Agreement with Merck Focused on Accelerating the Development of New Treatments for Neurodegenerative Diseases
Kineta Announces Strategic Research Collaboration and License Agreement with Merck Focused on Accelerating the Development of New Treatments for Neurodegenerative DiseasesStrategic Alliance Combines ...
Kineta Presents New Preclinical Data and Phase 1/2 Clinical Trial Design of KVA12.1 at the Tumor Myeloid-Directed Therapies Summit
Kineta Presents New Preclinical Data and Phase 1/2 Clinical Trial Design of KVA12.1 at the Tumor Myeloid-Directed Therapies Summit Seattle, WA — (June 17, 2022) Kineta, Inc. (“Kineta” or the “Compan ...
KVA 12.1 a novel fully human anti-VISTA antibody to treat cancer patients with advanced solid tumors
Shaarwari Sridhar, Scientist at Kineta Tumor Myeloid-Directed Therapies Summit 2022 | June 14, 2022
Kineta Announces Reverse Merger with NASDAQ-listed Yumanity Therapeutics (YMTX)
Yumanity Therapeutics announces definitive agreements for two strategic transactions Yumanity Therapeutics, Inc. to sell its clinical-stage product candidate YTX-7739 as well as its unpartnered disco ...